JP Morgan Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $61
JP Morgan analyst Anupam Rama initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $61.